Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

Stopped Cubist has reached an agreement with the FDA that enrollment in the DAP-RENSE-08-05 study can stop.

Conditions

• Complicated Skin and Skin Structure Infections
• S. Aureus Bacteremia
• Renal Impairment

Interventions

• DRUG: Vancomycin
• DRUG: Daptomycin
• DRUG: Semi-Synthetic Penicillin

Sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)